Equillium, Inc. (NASDAQ:EQ – Get Free Report) traded down 6.1% on Wednesday .The company traded as low as $0.37 and last traded at $0.38. 27,135 shares traded hands during trading, a decline of ...

LA JOLLA, Calif., May 06, 2025--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...

Graft versus host disease (GvHD) is an immune-driven disorder caused by a complex interplay between the donor's and recipient ...

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus ...

Celiac Disease Market Insight, Epidemiology And Market ForecastThe celiac disease treatment market is experiencing significant expansion, dr ...

Novartis, meanwhile, added an IL-15 drug when it acquired Calypso and its early-stage clinical candidate CALY-002 last year, while Equillium abandoned one dual IL-15/IL-21 inhibitor (EQ102 ...

Visit a quote page and your recently viewed tickers will be displayed here.